AIRS trades 6.6% below Wall Street's consensus target of $4.50.
Last 12 months price action with 12-month analyst target path
The base valuation assumes AIRS achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 5 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of July 8, 2026, AirSculpt Technologies, Inc. (AIRS) has a Wall Street consensus price target of $4.50, based on estimates from 5 covering analysts. With the stock currently trading at $4.22, this represents a potential upside of +6.6%. The company has a market capitalization of $298M.
Analyst price targets range from a low of $4.50 to a high of $4.50, representing a 0% spread in expectations. The median target of $4.50 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Hold, with 2 analysts rating the stock as a Buy or Strong Buy,3 rating it Hold, and 0 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, AIRS trades at a trailing P/E of -22.2x. Analysts expect EPS to grow +72.1% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
SKINThe Beauty Health Company | $144M | $1.11 | $1.53 | +37.8% | Hold | — | 14 |
INMDInMode Ltd. | $921M | $14.54 | $18.00 | +23.8% | Hold | 10.9x | 11 |
SSKNSTRATA Skin Sciences, Inc. | $705406 | $0.12 | — | — | — | — | — |
ESTAEstablishment Labs Holdings Inc. | $2.7B | $91.04 | $76.17 | -16.3% | Buy | — | 14 |
MDTMedtronic plc | $107.6B | $83.83 | $95.80 | +14.3% | Buy | 14.1x | 51 |
SYKStryker Corporation | $120.1B | $313.38 | $387.46 | +23.6% | Buy | 20.9x | 51 |
ISRGIntuitive Surgical, Inc. | $151.3B | $427.30 | $597.78 | +39.9% | Buy | 40.9x | 55 |
ABTAbbott Laboratories | $166.9B | $95.84 | $125.62 | +31.1% | Buy | 17.5x | 41 |
ZBHZimmer Biomet Holdings, Inc. | $17.5B | $89.41 | $96.33 | +7.7% | Hold | 10.5x | 42 |
LPGDorian LPG Ltd. | $1.7B | $39.10 | $55.00 | +40.7% | Hold | 9.1x | 9 |
Quick answers to the most common questions about buying AIRS stock.
The consensus price target for AIRS is $4.5, close to the current price of $4.22 (6.6% implied move). Based on 5 analyst estimates, the stock appears fairly valued near current levels.
AIRS has a consensus rating of "Hold" based on 5 Wall Street analysts. The rating breakdown is mixed, with 3 Hold ratings making up the largest segment. The consensus 12-month price target of $4.5 implies 6.6% upside from current levels.
AIRS's current price is $4.22 with a consensus target of $4.5 (6.6% implied move). Analyst estimates suggest the stock is fairly valued at current levels.
The most bullish Wall Street analyst has a price target of $4.5 for AIRS, while the most conservative target is $4.5. The consensus of $4.5 represents the median expectation. These targets typically reflect 12-month expectations.
AIRS is moderately covered, with 5 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 2 have Buy ratings, 3 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month AIRS stock forecast based on 5 Wall Street analysts shows a consensus price target of $4.5, with estimates ranging from $4.5 (bear case) to $4.5 (bull case). The median consensus rating is "Hold".
AIRS appears fairly valued according to analysts, with a "Hold" rating and minimal upside to the $4.5 target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
AIRS analyst price targets range from $4.5 to $4.5, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $4.5 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.